93 related articles for article (PubMed ID: 21091178)
1. Consumption of combined oral contraceptives and venous thromboembolism in Zagreb, Croatia.
Leppée M; Culig J; Eric M
Eur J Contracept Reprod Health Care; 2010 Dec; 15(6):445-6. PubMed ID: 21091178
[No Abstract] [Full Text] [Related]
2. The effect of a continuous regimen of drospirenone 3 mg/ethinylestradiol 30 microg on Cox-2 and Ki-67 expression in the endometrium.
Maia H; Casoy J; Athayde C; Valente Filho J; Coutinho EM
Eur J Contracept Reprod Health Care; 2010 Feb; 15(1):35-40. PubMed ID: 20063991
[TBL] [Abstract][Full Text] [Related]
3. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives.
Mawet M; Maillard C; Klipping C; Zimmerman Y; Foidart JM; Coelingh Bennink HJ
Eur J Contracept Reprod Health Care; 2015; 20(6):463-75. PubMed ID: 26212489
[TBL] [Abstract][Full Text] [Related]
4. Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen over six cycles.
Rabe T; Hartschuh E; Wahlstrom T; Höschen K; König S
Contraception; 2010 Oct; 82(4):358-65. PubMed ID: 20851230
[TBL] [Abstract][Full Text] [Related]
5. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits.
Machado RB; Pompei Lde M; Giribela AG; Giribela CG
Womens Health (Lond); 2011 Jan; 7(1):19-30. PubMed ID: 21175386
[TBL] [Abstract][Full Text] [Related]
6. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women.
Giribela CR; Consolim-Colombo FM; Nisenbaum MG; Moraes TL; Giribela AH; Baracat EC; Melo NR
Gynecol Endocrinol; 2015; 31(11):912-5. PubMed ID: 26172927
[TBL] [Abstract][Full Text] [Related]
7. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination.
Aydin K; Cinar N; Aksoy DY; Bozdag G; Yildiz BO
Contraception; 2013 Mar; 87(3):358-62. PubMed ID: 22898361
[TBL] [Abstract][Full Text] [Related]
8. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study.
Gargano V; Massaro M; Morra I; Formisano C; Di Carlo C; Nappi C
Contraception; 2008 Jul; 78(1):10-5. PubMed ID: 18555812
[TBL] [Abstract][Full Text] [Related]
9. [Some effects of hormonal contraceptives on the mammary tissue. Influence of duration of use and age os user].
de Sampaio Junior LF; Stecca J; Neme B
Matern Infanc (Sao Paulo); 1974; 33(4):509-30. PubMed ID: 4470961
[No Abstract] [Full Text] [Related]
10. Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo.
Anderson FD; Feldman R; Reape KZ
Contraception; 2008 Feb; 77(2):91-6. PubMed ID: 18226671
[TBL] [Abstract][Full Text] [Related]
11. Interference of drospirenone with the screening tests for primary aldosteronism.
Donckier JE
Acta Clin Belg; 2008; 63(4):289-90. PubMed ID: 19048711
[No Abstract] [Full Text] [Related]
12. Do drospirenone-containing oral contraceptives have a higher risk of VTE?
Ribowsky JH
JAAPA; 2011 Aug; 24(8):51-3. PubMed ID: 21850920
[No Abstract] [Full Text] [Related]
13. Norgestimate: overview of a monophasic formulation.
Anderson FD; Gillmer MD
Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():126-32. PubMed ID: 8260971
[No Abstract] [Full Text] [Related]
14. Cilest--a combined OC.
Drug Ther Bull; 1991 Dec; 29(26):103-4. PubMed ID: 1790761
[No Abstract] [Full Text] [Related]
15. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol.
Duijkers IJ; Klipping C; Grob P; Korver T
Eur J Contracept Reprod Health Care; 2010 Oct; 15(5):314-25. PubMed ID: 20695770
[TBL] [Abstract][Full Text] [Related]
16. The influence of combined oral contraceptives containing drospirenone on hypothalamic-pituitary-adrenocortical axis activity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome.
Macut D; Božić Antić I; Nestorov J; Topalović V; Bjekić Macut J; Panidis D; Kastratović Kotlica B; Papadakis E; Matić G; Vojnović Milutinović D
Hormones (Athens); 2015; 14(1):109-17. PubMed ID: 25402380
[TBL] [Abstract][Full Text] [Related]
17. Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density.
Nappi C; Di Spiezio Sardo A; Greco E; Tommaselli GA; Giordano E; Guida M
Obstet Gynecol; 2005 Jan; 105(1):53-60. PubMed ID: 15625142
[TBL] [Abstract][Full Text] [Related]
18. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial.
Seidman L; Kroll R; Howard B; Ricciotti N; Hsieh J; Weiss H
Contraception; 2015 Jun; 91(6):495-502. PubMed ID: 25746294
[TBL] [Abstract][Full Text] [Related]
19. Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives.
Hampton RM; Zhang HF; Barnowski C; Wan GJ
Contraception; 2008 Jun; 77(6):415-9. PubMed ID: 18477490
[TBL] [Abstract][Full Text] [Related]
20. Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel.
Heinemann K; Heinemann LA
J Fam Plann Reprod Health Care; 2011 Jul; 37(3):132-5. PubMed ID: 21659330
[No Abstract] [Full Text] [Related]
[Next] [New Search]
